🫀📉 Can more intensive LDL-lowering improve CT-FFR in stable chest pain? This new JACC study evaluates whether intensive lipid-lowering therapy (statin + ezetimibe) alters CT-derived fractional flow reserve (FFR-CT) — a noninvasive marker of lesion-specific ischemia — in patients with stable chest pain and coronary atherosclerosis. 🔍 Study essentials Patients with stable angina and coronary plaque on CT angiography were managed with aggressive lipid-lowering using statins plus ezetimibe, targeting substantial LDL-C reduction. FFR-CT was measured at baseline and on follow-up to assess functional changes in coronary physiology attributable to therapy. 📈 Key message The core focus — integrating structural and functional imaging — points to a key concept: lipid-lowering can potentially improve lesion physiology, not just plaque burden. By using FFR-CT (a validated surrogate for invasive FFR), the authors are examining whether aggressive LDL-reduction actually shifts physiological indices toward less ischemia. 🧠 Why this matters Lipid-lowering benefits have traditionally been shown at the event level (MI, death). Structural plaque regression with statins/ezetimibe is documented in IVUS and CT studies. But fewer data exist on functional improvement in coronary blood flow with therapy. Linking lipid therapy to improved FFR-CT suggests that LDL-lowering may not only slow plaque progression but also improve coronary physiology — a potential mechanistic bridge to clinical benefit. 📌 Bottom line: Intensive lipid-lowering might influence not only plaque morphology but lesion-specific ischemia as assessed noninvasively, expanding our understanding of how therapies translate into physiological improvement.